The Association for the Accreditation of Human Research Protection Programs, Inc.
has awarded accreditation to the National Cancer Institute Central Institutional Review Board—the first National Institutes of Health entity to earn this distinction.
NCI CIRB is one of five entities whose accreditation was approved at the December meeting of AAHRPP’s Council on Accreditation. Also accredited were two international organizations, including the first in Taiwan. The five newly accredited organizations are:
Accreditation of the NCI CIRB has implications for researchers and cancer patients nationwide because nearly all large multi-institutional treatment trials led by NCI’s Cooperative Group Program will now be conducted in accordance with AAHRPP’s high standards for protecting research participants.
“AAHRPP accreditation is an important affirmation of the high quality of the ethics reviews and the administrative processes conducted by NCI’s CIRB,” said Jeffrey Abrams, M.D., associate director of NCI's Cancer Therapy Evaluation Program, “and provides the impetus for us to expand the CIRB effort to cover phase 1-2 multicenter, NCI-sponsored trials in the future.”
NCI is one of 27 institutes and centers that form the NIH. The NCI CIRB will serve as the IRB for nearly all large multi-institutional treatment trials led by NCI’s Cooperative Group Program.
“NCI has long led the nation’s efforts to understand, treat and prevent cancer,” said Marjorie A. Speers, Ph.D., AAHRPP president and CEO. “By earning AAHRPP accreditation, NCI once again is demonstrating its leadership and commitment to high-quality research and to all those who are touched by cancer. Our hope is that other research organizations, including other research funders, will follow NCI’s example.”
The latest round of accreditations comes as AAHRPP marks the end of its first decade of accrediting research programs and organizations that meet high standards for research quality, ethics and protection of research participants. The diversity of the newly accredited organizations—a federal agency IRB, U.S. academic medical centers and international hospitals―underscores the inroads AAHRPP has made across the research enterprise, in the U.S. and worldwide.
“From the beginning, AAHRPP’s goal has been to protect as many participants as possible, while ensuring that the world reaps the benefits of research,” Speers said. “These accreditations, of key players in Asia and the U.S., represent another significant step forward in achieving that goal.”
AAHRPP accreditation is available to U.S. and international organizations that conduct biomedical, behavioral or social sciences research involving human participants. To date, AAHRPP has accredited organizations in 46 states, Canada, China, India, Korea, Singapore and Taiwan.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.